AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02426190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Recumbent or Nu-step bike
Description: This is the active comparator of the trial that participants are asked to use either a recumbent or Nu-step bike normally seen in an outpatient physical therapy clinic to warm-up during a physical therapy session following a single total knee replacement.
Study NCT00799045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients will be randomized either to aspirin (80 mg/day) or aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.
Study NCT00799045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Patients will be randomized either to aspirin (80 mg/day) or aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.
Study NCT00932620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SIMVASTATIN 40 mg
Description: SIMVASTATIN 40 mg/day for 3 months
Study NCT00932620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SIMVASTATIN/EZETIMIBE 10/10 mg
Description: SIMVASTATIN/EZETIMIBE 10/10 mg/day for 3 months
Study NCT02954419 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT01956136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music-based Neurological Rehabilitation (MBNR)
Description: Music-based Neurological Rehabilitation (MBNR) will involve 10 weeks of individual training (30 sessions, 1 hour per session, 3 days per week) given by a trained music therapist. The MBNR protocol utilizes structured cognitive-motor training with drums (drum set, djembe drums) and creative musical expression (music playing, song writing) with piano that are geared towards engaging and training attention, executive functions, working memory, and upper-extremity functions and for enhancing emotional self-expression, adjustment, and mood after TBI.
Study NCT01956136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care (SC)
Description: Standard Care (SC) consists of other types of conventional rehabilitation (physical therapy, occupational therapy, speech therapy, and/or neuropsychological rehabilitation) and medical care for TBI that the patients receive in Finnish private or public health care.
Study NCT02069730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: If no druggable aberrations are identified on the molecular profiling analysis, then patients will receive unmatched treatment with Selinexor, a selective inhibitor of nuclear export (SINE).
Study NCT02069730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR or HER2 Inhibitor
Description: If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with EGFR or HER2 Inhibitor
Study NCT02069730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGFR Inhibitor
Description: If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with FGFR Inhibitor
Study NCT02069730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-KIT Inhibitor
Description: If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with C-KIT Inhibitor
Study NCT02069730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-androgen
Description: If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with Anti-androgens
Study NCT02069730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOTCH Inhibitor
Description: If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with NOTCH Inhibitor
Study NCT00355615 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin
Description: oral
Study NCT00355615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT02069730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK or PI3K Inhibitor
Description: If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with MEK or PI3K Inhibitor
Study NCT03068416 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR T cells
Description: Autologous CD19-targeting, 3rd generation CAR T cells
Study NCT04244864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cross-sectoral psychosocial intervention
Description: The intervention seeks to integrate working with social stressors alongside treatment for trauma-related mental health problems. This is done in two ways; by a cross-sectoral collaboration with the patient's case counsellor in the municipality including three collaborative meetings and by a systematic focus on social stressors during the treatment.
Study NCT04244864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: Medical doctor, 10 sessions: Pharmacological treatment according to standard algorithm and psychoeducation.~Psychologist 16-21 sessions: Manual-based cognitive behavioural therapy.
Study NCT04244864 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Medical doctor, 10 sessions: Pharmacological treatment according to standard algorithm and psychoeducation.~Psychologist 16-21 sessions: Manual-based cognitive behavioural therapy.
Study NCT00594542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: Each group is the appropriate concentration of lidocaine with epinephrine for local anesthesia at the beginning of each Mohs stage and the reconstruction.
Study NCT00694096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Imaging studies with complete analyses will be provided on all patients prior to institution of sunitinib therapy as well as after therapy at various early time points (1 week in 5 patients, 2 weeks in 5 patients, 3 weeks in 5 patients or 4 weeks in 5 patients) after institution of sunitinib therapy at 37.5 mg orally/day.~Imaging studies include:~FDG-PET scans FLT-PET scans H215O-PET scans DCE-MRI scans
Study NCT00725959 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online social networking HIV prevention
Description: messages about HIV posted in online social networking sites
Study NCT02430896 — intervention group
Intervention type: DRUG
Intervention: Methylphenidate (MPH)
Description: Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
Study NCT02430896 — intervention group
Intervention type: DRUG
Intervention: Atomoxetine
Description: Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
Study NCT00496483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LCP Tacro (tacrolimus)
Description: Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.~Other Names:~Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets.
Study NCT00496483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.~Other Names:~Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets.
Study NCT00953524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA)
Description: 0.5 mL, Intramuscular on Day 0 and on Day 21
Study NCT00953524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA)
Description: 0.5 mL, Intramuscular on Day 0 and Day 21
Study NCT00953524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)
Description: 0.5 mL, Intramuscular on Day 0 and day 21
Study NCT00953524 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline solution (placebo)
Description: 0.5 mL, Intramuscular on Day 0 and Day 21
Study NCT03023826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626 (R-Fasting)
Description: Administered orally
Study NCT03023826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626 (T1-Fasting)
Description: Administered orally
Study NCT03023826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626 (T1-Fed)
Description: Administered orally
Study NCT04540458 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 3D printed model
Description: Mother or Mother/Father is given 3D printed model of fetus' face
Study NCT04540458 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Mother or Mother/Father is given a picture of 3D ultrasound of fetus
Study NCT02572232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combitube, Easytube, Laryngeal masks
Description: Supraglottic airway device
Study NCT00725959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online social networking HIV prevention
Description: messages about HIV posted in online social networking sites
Study NCT02055014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Study NCT02055014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Study NCT02055014 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duodenal-jejunal bypass liner - Endobarrier device
Study NCT01093547 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples
Description: Samples taken monthly
Study NCT02142283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trevo Thrombectomy Procedure
Description: stent retriever; intended to restore blood flow in the neurovasculature by removing thrombus (clot)
Study NCT02142283 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Management
Description: Standard of Care not including mechanical thrombectomy, no intra arterial treatment, may include aspirin, therapy etc
Study NCT01093547 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measure of peritoneal ultrafiltrates
Description: Measured by the investigators intermittently and by the patients themselves on a monthly basis
Study NCT02142283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Management
Description: Standard of Care not including mechanical thrombectomy, no intra arterial treatment, may include aspirin, therapy etc
Study NCT04359290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib administration
Description: Ruxolitinib will be administered p.o. or by gavage feeding starting with 2 x 10mg or 2 x 15mg bid dose at day 1 according to the investigator's decision and can be increased up to 2 x 15mg bid from day 2 to day 28 (max) (depending on platelet counts and renal function). Ruxolitinib will be administered in the morning and evening. Dosing will be adjusted according to toxicity and kidney function.If the patient is discharged before day 28, the therapy will be discontinued for discharge.
Study NCT01665430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered at 8 mg/kg intravenous infusion every 4 weeks, up to 104 weeks.
Study NCT00168103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C1 Esterase Inhibitor
Description: Single application of C1-INH administered intravenously by slow injection or infusion at a recommended rate of 4mL/min.
Study NCT00168103 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single application of physiological saline solution equivalent to the volume calculated for subjects in the C1-INH 20 U/kg bw arm.
Study NCT01430507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revamilast
Description: Tablet, Low dose, Once daily for 12 weeks
Study NCT01430507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revamilast
Description: Tablet, Medium dose, Once daily for 12 weeks
Study NCT01430507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revamilast
Description: Tablet, High dose, Once daily for 12 weeks
Study NCT01430507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Matching Placebo in triple dummy format, Tablet, Once daily for 12 weeks
Study NCT01371643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide LAR
Study NCT01371643 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transsphenoidal surgery
Study NCT03249935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 1 gm PO single dose given as directly observed
Study NCT02111135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: b-OPV
Study NCT02111135 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: b-OPV
Study NCT02111135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: m-OPV2
Study NCT02111135 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: m-OPV2
Study NCT02111135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: m-IPV HD
Study NCT02111135 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: t-IPV
Study NCT04374591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Bicarbonate
Description: Inhalation of Sodium Bicarbonate 8.4% via nebulizer
Study NCT04374591 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sodium Bicarbonate
Description: Inhalation of Sodium Bicarbonate 8.4% via nebulizer
Study NCT01799239 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test product
Description: The test product consists of an adhesive with a new top film
Study NCT01799239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test product
Description: The test product consists of an adhesive with a new top film
Study NCT01799239 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SenSura
Description: SenSura is the CE-marked and commercially available comparator product
Study NCT01799239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura
Description: SenSura is the CE-marked and commercially available comparator product
Study NCT00315198 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye Patch
Description: 2 hours daily patching
Study NCT00315198 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Near activities
Description: near visual activities while patching
Study NCT00315198 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distance activities
Description: distance visual activities while patching
Study NCT04304391 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resective Gingival Surgery
Description: Gingivectomy and gingivoplasty:Resective gingival surgical procedured
Study NCT03325933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Load/Low Rep Resistance Training
Description: Participants will be prescribed High Load/Low Rep resistance training.
Study NCT03325933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Load/High Rep Resistance Training
Description: Participants will be prescribed Low Load/High Rep resistance training.
Study NCT01104922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered for 3 weekly doses commencing one week prior to stereotactic radiosurgery treatment as follows: \* Cetuximab 400 mg / m2 day -7 (1 week prior to initiation of radiosurgery) \* Cetuximab 250 mg/m2 days 0 and +8 (i.e. during the first and second week of fractionated stereotactic radiosurgery) Cetuximab will be administered at 400 mg/m2 IV over 120 minutes on day -7 (loading dose) and 250 mg/m2 IV on days 0 and 8 during the course of stereotactic radiosurgery.
Study NCT01104922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery
Description: Fractionated stereotactic radiosurgery, 8.0 Gy per fraction for 5 fractions (total: 40.0 Gy)
Study NCT03685643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention - Dating application topic
Description: The intervention will consist of multimedia content to promote the safe usage of dating applications and raise awareness of the risks associated with dating application usage. The intervention will be delivered one-time in a classroom setting.
Study NCT03685643 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control - Health and exercise topic
Description: The placebo control will consist of multimedia content regarding exercise and healthy living. It will be delivered once-time in a classroom setting.
Study NCT02460094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB092
Description: See Arm Descriptions for dosing information.
Study NCT02460094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See Arm Descriptions for dosing information. (0.9% Sodium Chloride for Injection or 5% Dextrose Injection if Sodium Chloride is not available)
Study NCT03378427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid Phosphate 200 MG [Sivextro]
Description: Antibiotic treatment (monotherapy or combination) targeting bacteria cultured from per operative samples.
Study NCT03001765 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intensive Monitoring Strategy: Reveal LINQ™ Insertable Cardiac Monitoring System.
Description: Intensive monitoring strategy of discharge from Emergency Department with 30 day SEEQ external monitor, followed by implantable cardiac Reveal LINQ monitor if negative 30 day result.
Study NCT04749511 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Extrambulatory digital PROMs detection
Description: The aim of the study is to investigate the validity of an alternative method of evaluating PROMs in which the questionnaire will be administered to the patient digitally (Google Forms) in an out-of-patient setting.
Study NCT03609021 — intervention group
Intervention type: PROCEDURE
Intervention: Screening Mammography
Description: Provide bilateral mammogram
Study NCT03609021 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample
Study NCT02740634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 AV 1451
Description: Tau binding agent
Study NCT02740634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-11 PiB
Description: Amyloid binding agent
Study NCT03994510 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical and biological assessments - a 5 Years follow-up
Description: During each visit, a clinical evaluation will be carried out, as well as the filling of hetero-questionnaires and self-questionnaires. Two biological collections will be made: one during the inclusion visit, and the other during the last visit, 5 years after inclusion.
Study NCT02616562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somapacitan
Description: Administered subcutaneously (s.c., under the skin) once-weekly.
Study NCT03644173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Resilience Empowerment Program including 5 sessions with health coaches
Description: 5 coaching sessions that will take place either in-person or over the phone with a research nurse (RN)-Health Coach. During the sessions, the health coach will focus on introducing the 5 pillars of health and well-being: sleep, activity, purpose, nutrition and resilience. Will introduce breathing techniques participants and will teach patients how to acquire mind-body skills to assist in stress management, learn to thrive by building resilience, feel empowered to manage their health, gain self-care skills to decrease anxiety, pain and nausea naturally, control the stress response and trigger the relaxation response to promote well-being and discover what foods fuel the body in preparation for healing, during recovery and overall health.
Study NCT02616562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: somapacitan
Description: Administered subcutaneously (s.c., under the skin) once-weekly.
Study NCT02616562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norditropin® FlexPro® pen
Description: Administered subcutaneously (s.c., under the skin) once daily.